[1] BAGLIN T, KEELING D, KITCHEN S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology [J]. Brit J Haematol, 2012, 159(4): 427-429.
[2] KUBITZA D, BECKA M, WENSING G,et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Ⅹa inhibitor—after multiple dosing in healthy male subjects[J]. Eur J Clin Pharmacol, 2005, 61(12): 873-880.
[3] KUBITZA D, BECKA M, VOITH B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Ⅹa inhibitor[J]. Clin Pharmacol Ther, 2005, 78(4): 412-421.
[4] MUECK, BECKA, KUBITZA, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Ⅹa inhibitor-in healthy subjects [J]. Int J Clin Pharm Ther, 2007, 45(6): 335-344.
[5] ZHAO X, SUN P, ZHOU Y,et al. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Ⅹa inhibitor rivaroxaban in healthy Chinese subjects [J]. Br J Clin Pharmacol, 2009, 68(1): 77-88.
[6] RAGHAVAN N, FROST C E, YU Z,et al. Apixaban metabolism and pharmacokinetics after oral administration to humans[J]. Drug Metab Dispos, 2008, 37(1): 74-81.
[7] FROST C, WANG J, NEPAL S, et al. Apixaban, an oral, direct factor Ⅹa inhibitor:Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects[J]. Br J Clin Pharmacol, 2013, 75(2): 476-487.
[8] FROST C, NEPAL S, WANG J,et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Ⅹa inhibitor, in healthy subjects[J]. Br J Clin Pharmacol, 2013, 76(5): 776-786.
[9] OGATA K, MENDELL-HARARY J, TACHIBANA M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Ⅹa inhibitor edoxaban in healthy volunteers[J]. J Clin Pharmacol, 2010, 50(7): 743-753.
[10] HUANG L,LIU F,LI Y Z. The pharmacological effects and clinical applicationof non-vitamin K oral factor Ⅹa inhibitor rivaroxaban[J].Chin Pharm J(中国药学杂志),2010, 45(21): 1682-1684.
[11] STANGIER J, RATHGEN K, STHLE H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatranetexilate, a new oral direct thrombin inhibitor, in healthy male subjects [J]. Br J Clin Pharmacol, 2007, 64(3): 292-303.
[12] LI X C,CHEN J,XU X W. The new factor Ⅱa inhibitor——dabigatranetexilate[J]. Chin Pharm J( 中国药学杂志), 2011, 46(9):718-720.
[13] HILLARP A, BAGHAEI F, FAGERBERG BLIXTER I, et al. Effects of the oral, direct factor Ⅹa inhibitor rivaroxaban on commonly used coagulation assays [J]. J Thromb Haemost, 2011, 9(1): 133-139.
[14] SAMAMA M M, MENDELL J, GUINET C, et al.In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux [J]. Thromb Res, 2012, 129(4): 77-82.
[15] VAN BLERK M, BAILLEUL E, CHATELAIN B, et al.Influence of dabigatran and rivaroxabanon routine coagulation assays. A nationwide Belgian survey[J]. Thromb Haemost, 2015,113(1): 154-164.
[16] HELIN T A, PAKKANEN A, LASSILA R, et al. Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories[J].Clin Chem, 2013, 59(5): 807-814.
[17] SCHMITZ E M H, BOONEN K, VAN DEN HEUVEL D J A, et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants [J]. J Thromb Haemost, 2014, 12(10): 1636-1646.
[18] SAMAMA M M, AMIRAL J, GUINET C, et al.An optimised, rapid chromogenic assay, specific for measuring direct factor Ⅹa inhibitors (rivaroxaban) in plasma [J]. Thromb Haemost, 2010, 104(5):1078-1079.
[19] SAMAMA M M, CONTANT G, SPIRO T E, et al. Evaluation of the anti-factor Ⅹa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls [J]. Thromb Haemost, 2012, 107(2): 379-387.
[20] HILLARP A, GUSTAFSSON K M, FAXLV L, et al. Effects of the oral, direct factor Ⅹa inhibitor apixaban on routine coagulation assays and anti-FXa assays [J] .J Thromb Haemost, 2014, 12(9): 1545-1553.
[21] BECKER R C, YANG H, BARRETT Y, et al. Chromogenic laboratory assays to measure the factor Ⅹa-inhibiting properties of apixaban—an oral, direct and selective factor Ⅹa inhibitor [J]. J Thromb Thrombolysis, 2011, 32(2):183-187.
[22] MORISHIMA Y, KAMISATO C. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay[J]. Am J Clin Pathol, 2015, 143(2): 241-247.
[23] KITCHEN S, GRAY E, MACKIE I, et al. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology[J]. Br J Haematol, 2014,166(6):830-841.
[24] CUSHMAN M, LIM W, ZAKAI N A. Clinical practice guide on antithrombotic drug dosing and management of antithrombotic drug-associated bleeding complications in adults[J/OL][2015-03-01].American Society of Hematology,2014[July 16, 2014]. http://www.hematology.org/Clinicians/Guidelines-Quality/Quick-Ref/2869.aspx.
[25] HEIDBUCHEL H, VERHAMME P, ALINGS M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation[J]. Europace, 2013, 15(5): 625-651.
[26] DOUXFILS J, MULLIER F, ROBERT S, et al. Impact of dabigatran on a large panel of routine or specificcoagulation assays. Laboratory recommendations for monitoring of dabigatranetexilate[J]. Thromb Haemost, 2012,107(5):985-997.
[27] DAGER W E, GOSSELIN R C, KITCHEN S, et al. Dabigatran effects on the international normalizedratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study [J]. Ann Pharmacother , 2012,46(12): 1627-1636.
[28] VAN RYN J, BARUCH L, CLEMENS A. Interpretation of point-of-care INR results in patients treatedwith dabigatran [J]. Am J Med, 2012,125(4):417-420.
[29] ANTOVIC J P, SKEPPHOLM M, EINTREI J, et al. Evaluation of coagulation assays versus LC-MS/MSfor determinations of dabigatran concentrations in plasma [J]. Eur J Clin Pharmacol, 2013, 69(11):1875-1881.
[30] GOSSELIN R C, DWYRE D M, DAGER W E. Measuring dabigatran concentrations using a chromogenicecarin clotting time assay [J]. Ann Pharmacother, 2013, 47(12):1635-1640.
[31] VAN RYN J, STANGIER J, HAERTTER S, et al. Dabigatranetexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity [J] .Thromb Haemost, 2010,103(6):1116-1127.
[32] STANGIER J, FEURING M. Using the HEMOCLOT direct thrombin inhibitor assay to determineplasma concentrations of dabigatran [J]. Blood Coagul Fibrinolysis, 2012, 23(2):138-143.
[33] FENGER-ERIKSEN C, MüNSTER A M, GROVE E L. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications [J]. Acta Anaesth Scand, 2014, 58(6): 651-659.
[34] SONG S, KANG D, HALIM A B, et al.Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment[J]. J Clin Pharmacol, 2014, 8(54): 910-916.
[35] LIPPI G, FAVALORO E J. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? [J]. Clin Chem Lab Med, 2015, 53(2): 185-197.
[36] ALTMAN R, GONZALEZ CD.Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs[J] .Thromb J, 2014, 12(1):1-7.
[37] FAVALORO E J, LIPPI G. The new oral anticoagulants and the future of haemostasis laboratory testing [J]. Biochem Med (Zagreb), 2012, 22(3): 329-341.
[38] EXNER T, ELLWOOD L, RUBIE J, et al. Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study [J]. Thromb Haemost, 2013, 109(4): 762-765.
[39] MANI H, HERTH N, KASPER A, et al. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant [J]. Ther Drug Monit, 2014, 36(5): 624-631.
[40] CASUTT M, KONRAD C, SCHUEPFER G. Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM^TM[J]. Der Anaesthesist, 2012, 61(11): 948-953.
[41] ELLER T, BUSSE J, DITTRICH M, et al. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests [J]. Clin Chem Lab Med, 2014, 52(6):835-844.
[42] ADELMANN D, WIEGELE M, WOHLGEMUTH R K, et al. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry[J].Thromb Res, 2014, 134(4): 918-923.
[43] MEYER DOS SANTOS S, ZORN A, GUTTENBERG Z, et al.A novel μ-fluidic whole blood coagulation assay based on Rayleigh surface-acoustic waves as a point-of-care method to detect anticoagulants [J].Biomicrofluidics, 2013, 7(5):56502.
[44] HARENBERG J, DU S, KRMER S, et al.Novel methods for assessing oral direct factor Ⅹa and thrombin inhibitors: use of point-of-care testing and urine samples[J]. Semin Thromb Hemost, 2013, 39(1): 66-71.
[45] HARENBERG J, KRMER S, DU S, et al. Concept of a point of care test to detect new oral anticoagulants in urine samples [J]. Thromb J, 2013, 11(1):15-19.